Min H Kang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8906073/publications.pdf

Version: 2024-02-01

86 papers	4,287 citations	117571 34 h-index	110317 64 g-index
86 all docs	86 docs citations	86 times ranked	6779 citing authors

#	Article	IF	Citations
1	Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy. Clinical Cancer Research, 2009, 15, 1126-1132.	3.2	875
2	Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatric Blood and Cancer, 2010, 55, 26-34.	0.8	195
3	A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer. Journal of Experimental Therapeutics and Oncology, 2002, 2, 325-332.	0.5	189
4	Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood, 2007, 110, 2057-2066.	0.6	142
5	DNA-PK as an Emerging Therapeutic Target in Cancer. Frontiers in Oncology, 2019, 9, 635.	1.3	134
6	Mechanism of Synergy of N-(4-Hydroxyphenyl)Retinamide and ABT-737 in Acute Lymphoblastic Leukemia Cell Lines: Mcl-1 Inactivation. Journal of the National Cancer Institute, 2008, 100, 580-595.	3.0	115
7	Role of OCT4 in cancer stem-like cells and chemotherapy resistance. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165432.	1.8	104
8	Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research, 2015, 21, 819-832.	3.2	100
9	Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833. Journal of Clinical Oncology, 2001, 19, 832-842.	0.8	95
10	Initial testing (stage 1) of AZD6244 (ARRYâ€142886) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 668-677.	0.8	94
11	Initial testing of a monoclonal antibody (IMCâ€A12) against IGFâ€1R by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 921-926.	0.8	89
12	Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics, 2010, 9, 101-112.	1.9	89
13	Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1291-1304.	1.1	88
14	Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing's Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression. Clinical Cancer Research, 2015, 21, 1139-1150.	3.2	82
15	National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing. Pediatric Blood and Cancer, 2011, 56, 239-249.	0.8	77
16	Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 636-639.	0.8	73
17	Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium. Pediatric Blood and Cancer, 2013, 60, 1801-1808.	0.8	72
18	Initial testing of the replication competent Seneca Valley virus (NTXâ€010) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 295-303.	0.8	70

#	Article	IF	Citations
19	Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clinical Cancer Research, 2016, 22, 621-632.	3.2	68
20	Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth. International Journal of Molecular Sciences, 2021, 22, 6526.	1.8	67
21	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood and Cancer, 2016, 63, 1349-1356.	0.8	66
22	Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. Pediatric Blood and Cancer, 2015, 62, 91-98.	0.8	65
23	Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models. Clinical Cancer Research, 2019, 25, 2278-2289.	3.2	57
24	Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 633-641.	0.8	55
25	Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Research, 2016, 76, 5798-5809.	0.4	52
26	Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1126-1133.	0.8	51
27	Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts. PLoS ONE, 2012, 7, e33894.	1.1	49
28	Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives. Experimental Biology and Medicine, 2017, 242, 1178-1184.	1.1	47
29	Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leukemia Research, 2012, 36, 342-349.	0.4	44
30	Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 55, 1329-1337.	0.8	43
31	C22:0- and C24:0-dihydroceramides Confer Mixed Cytotoxicity in T-Cell Acute Lymphoblastic Leukemia Cell Lines. PLoS ONE, 2013, 8, e74768.	1.1	40
32	Initial testing of the CENPâ€E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 916-923.	0.8	39
33	Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 1266-1274.	0.8	38
34	Initial testing of topotecan by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2010, 54, 707-715.	0.8	37
35	Testing of the Akt/PKB inhibitor MKâ€2206 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 518-524.	0.8	36
36	Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 191-199.	0.8	35

#	Article	IF	Citations
37	Reactive Oxygen Speciesâ€“Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies. Molecular Cancer Therapeutics, 2017, 16, 649-661.	1.9	35
38	Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposure. British Journal of Pharmacology, 2011, 163, 1263-1275.	2.7	32
39	Initial testing of the hypoxiaâ€activated prodrug PRâ€104 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2011, 57, 443-453.	0.8	31
40	Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a Î³â€secretase inhibitor targeting notch signaling. Pediatric Blood and Cancer, 2012, 58, 815-818.	0.8	31
41	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023.	0.8	31
42	Initial testing of the investigational NEDD8â€activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 246-253.	0.8	30
43	Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPTâ€330): A report from the pediatric preclinical testing program. Pediatric Blood and Cancer, 2016, 63, 276-286.	0.8	28
44	Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, 1860-1867.	0.8	27
45	Initial Testing (Stage 1) of MKâ€8242â€"A Novel MDM2 Inhibitorâ€"by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 1744-1752.	0.8	27
46	Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia. Cell Death and Disease, 2018, 9, 925.	2.7	26
47	Phase I Study of Fenretinide Delivered Intravenously in Patients with Relapsed or Refractory Hematologic Malignancies: A California Cancer Consortium Trial. Clinical Cancer Research, 2017, 23, 4550-4555.	3.2	23
48	Initial testing of JNJâ€26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 329-332.	0.8	22
49	Metabolic characteristics of 13â€cisâ€retinoic acid (isotretinoin) and antiâ€tumour activity of the 13â€cisâ€retinoic acid metabolite 4â€oxoâ€13â€cisâ€retinoic acid in neuroblastoma. British Journal of Pharmacology, 2014, 171, 5330-5344.	2.7	21
50	Initial testing (stage 1) of SGIâ€1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 749-752.	0.8	20
51	Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2014, 61, 1486-1489.	0.8	19
52	Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2011, 57, 268-274.	0.8	18
53	P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. International Journal of Cancer, 2017, 141, 405-413.	2.3	18
54	Prion protein modulates endothelial to mesenchyme-like transition in trabecular meshwork cells: Implications for primary open angle glaucoma. Scientific Reports, 2019, 9, 13090.	1.6	18

#	Article	IF	Citations
55	MYC transcription activation mediated by OCT4 as a mechanism of resistance to 13-cisRA-mediated differentiation in neuroblastoma. Cell Death and Disease, 2020, 11, 368.	2.7	18
56	Antineoplastic Agents Targeting Sphingolipid Pathways. Frontiers in Oncology, 2020, 10, 833.	1.3	18
57	Testing of the topoisomerase 1 inhibitor Genzâ€644282 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 58, 200-209.	0.8	16
58	Fenretinide via NOXA Induction, Enhanced Activity of the BCL-2 Inhibitor Venetoclax in High BCL-2â€“Expressing Neuroblastoma Preclinical Models. Molecular Cancer Therapeutics, 2019, 18, 2270-2282.	1.9	16
59	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2017, 64, e26263.	0.8	15
60	Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2012, 59, 185-188.	0.8	14
61	Initial testing (stage 1) of the antiâ€microtubule agents cabazitaxel and docetaxel, by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2015, 62, 1897-1905.	0.8	14
62	Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2013, 60, E42-5.	0.8	11
63	Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. Experimental Biology and Medicine, 2014, 239, 1390-1402.	1.1	11
64	Initial testing of aplidin by the pediatric preâ€clinical testing program. Pediatric Blood and Cancer, 2009, 53, 509-512.	0.8	10
65	Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia. Anti-Cancer Drugs, 2019, 30, 117-127.	0.7	10
66	A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors. Cancer Chemotherapy and Pharmacology, 2021, 87, 525-532.	1.1	10
67	Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Research Notes, 2014, 7, 256.	0.6	9
68	Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatric Blood and Cancer, 2012, 59, 753-755.	0.8	8
69	Vorinostat and fenretinide synergize in preclinical models of T-cell lymphoid malignancies. Anti-Cancer Drugs, 2021, 32, 34-43.	0.7	8
70	Methotrexate and aminopterin exhibit similar in vitro and in vivo preclinical activity against acute lymphoblastic leukaemia and lymphoma. British Journal of Haematology, 2009, 145, 389-393.	1.2	7
71	Preservation of high glycolytic phenotype by establishing new acute lymphoblastic leukemia cell lines at physiologic oxygen concentration. Experimental Cell Research, 2015, 334, 78-89.	1.2	7
72	Mithramycin induces promoter reprogramming and differentiation of rhabdoid tumor. EMBO Molecular Medicine, 2021, 13, e12640.	3.3	7

#	Article	IF	Citations
73	Analysis of fenretinide and its metabolites in human plasma by liquid chromatographyâ€“tandem mass spectrometry and its application to clinical pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2017, 132, 117-124.	1.4	6
74	pH gradient-liquid chromatography tandem mass spectrometric assay for determination of underivatized polyamines in cancer cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1085, 21-29.	1.2	6
75	Assessing Combinations of Cytotoxic Agents Using Leukemia Cell Lines. Current Drug Targets, 2007, 8, 765-771.	1.0	6
76	Hydrophilic interaction liquid chromatographyâ€“tandem mass spectrometric approach for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1112, 16-23.	1.2	5
77	Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatric Blood and Cancer, 2011, 57, 606-611.	0.8	4
78	c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins Î±vÎ²3 and Î±vÎ²5. PLoS ONE, 2012, 7, e42291.	1.1	4
79	Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. Pediatric Blood and Cancer, 2018, 65, e27447.	0.8	4
80	Phase I Trial of Fenretinide (4-HPR) Intravenous Emulsion for Hematologic Malignancies.. Blood, 2007, 110, 2581-2581.	0.6	4
81	PPE decontamination to overcome PPE shortage in rural area during pandemic. Infection Prevention in Practice, 2021, 3, 100145.	0.6	3
82	Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia. Pediatric Blood and Cancer, 2012, 58, 994-997.	0.8	2
83	Development of cellâ€based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNAâ€PKcs and OCT4â€“MK2 interactions. Biotechnology and Bioengineering, 2021, 118, 1987-2000.	1.7	2
84	Phase I trial of fenretinide (4-HPR) intravenous emulsion in hematologic malignancies: A California Cancer Consortium study (PhI-42).. Journal of Clinical Oncology, 2012, 30, 8073-8073.	0.8	2
85	Simultaneous Determination of Safingol and d-erythro-Sphinganine in Human Plasma by LC with Fluorescence Detection. Chromatographia, 2010, 71, 1087-1091.	0.7	1
86	Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program. Pediatric Blood and Cancer, 2016, 63, 443-450.	0.8	0